E for L Aim Public Company (EFORL) Fair Value & Analysis
Healthcare · TH · Market cap 520M THB
Fair value as of: Jul 20, 2026
From 24 valuation models · updated 21 days ago
Share price −15.4% over the past month.
A solid business, screening 73% undervalued on our models.
What matters now
- The price is below even our cautious bear case (0.1400 THB). The market is more pessimistic than our downside scenario.
- Solid quality (60/100) at a price below fair value, the discount is the argument here, not the business quality.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 20, 2026.
How to read this chart
60‑month range 0.0800 THB – 2.80 THB · fair‑value band 0.1400 THB – 0.2400 THB · the 0.1100 THB price screens below the 0.1900 THB fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 20, 2026.
Analysis
E for L Aim Public Company (EFORL) currently trades at 0.1100 THB, while our model-based Fair Value estimate is 0.1900 THB, implying the stock looks roughly 72.7% undervalued today. The Quality Score stands at 60/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, E for L Aim Public Company generated revenue of 1.3B THB at a net margin of 4.0%. Revenue declined 12.6% year over year. It earns a return on equity of 8.9%. Net debt stands at 277M THB. Fundamentals as of Jul 20, 2026
Our scenario range runs from 0.1400 THB (bear case) to 0.2400 THB (bull case); at 0.1100 THB, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 45% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 2% fair-value upside, at 73%, EFORL screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: DCF Models (0.3100 THB) versus Economic Profit (0.0900 THB). Highest evidence: Growth DCF (80).
Notify me when EFORL reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 20, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 59 · Market factors (momentum, volatility) 27
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
E for L Aim Public Company Limited, together with its subsidiaries, engages in the distribution of medical devices and equipment in Thailand, the United States, Europe, and Asia.
Full company description
E for L Aim Public Company Limited, together with its subsidiaries, engages in the distribution of medical devices and equipment in Thailand, the United States, Europe, and Asia. The company offers medical devices, including patient and central monitor systems, defibrillator, automated external defibrillator, electrocardiographs, electroencephalogram, PSG system, and accessories and consumables, as well as ICU, transport, and MRI ventilators, anesthesia delivery system, incubator and radiant warmer, phototherapy, spirometer, pulmonary function lab, and cardiopulmonary exercise testing devices. It also provides handheld and ultrasound scanners, high flow oxygen therapy, ceiling pendant, hemodialysis machine, continuous renal replacement therapy, ozone hybrid, patients and medical devices tracking system, MRI infusion and monitor systems, MRI ferrous metal detector, video laryngoscope, hydrogen peroxide plasma sterilizing, and picture archiving and communication devices, as well as clean rooms, anesthesia record system, ECG viewer system, CIS for hemodialysis, telemedicine, telehealth, and PM and after-sale services. In addition, the company offers diagnosis and laboratory products, such as clinical chemistry, hematology, and immunoassay systems, blood gas and banking, urinalysis, hemoglobin A1C analyzer, automated immunoassay analyzer, rapid test kit, coagulation, POCT clinical chemistry analyzers, air purifier, and laboratory information system. Further, it distributes microscopes for life sciences comprising educational microscopes, clinical and laboratory microscopes, and microscopes for biological scientific research. The company was formerly known as Absolute Impact Public Company Limited and changed its name to E for L Aim Public Company Limited in September 2013. E for L Aim Public Company Limited was incorporated in 2005 and is based in Bangkok, Thailand.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
E for L Aim Public Company reported revenue of 1.3B THB in FY2025 versus 2.2B THB in FY2021, a compound −11.9%/yr. Reported net income was 44.6M THB in FY2025, compounding −51.6%/yr from FY2021.
of which total revenue −8.2 pp · buybacks/dilution −11.4 pp
Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).
Watch EFORL: get an alert when its fair value changes →
Peer Group
Medical Distribution · 81 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Distribution median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Insider activity: 45/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Distribution stocks, each showing price versus our Fair Value estimate (as of Jul 20, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| McKesson Corporation MCK | $805.96 | $819.31 | +2% |
| Cencora, Inc COR | $303.44 | $175.74 | -42% |
| Cardinal Health, Inc CAH | $224.94 | $141.77 | -37% |
| Henry Schein, Inc HSIC | $87.82 | $74.67 | -15% |
| Shanghai Pharmaceuticals Holding 601607 | ¥16.70 | ¥33.96 | +103% |
| Sinopharm Group 1099 | HK$16.74 | HK$61.33 | +266% |
| Galenica AG GALE | CHF 87.05 | CHF 61.79 | -29% |
| Guangzhou Baiyunshan Pharmaceutical Holdings 600332 | ¥21.50 | ¥28.65 | +33% |
| Jointown Pharmaceutical Group 600998 | ¥4.99 | ¥9.84 | +97% |
| Asker Healthcare Group ASKER | kr 79.45 | kr 25.69 | -68% |
Compare E for L Aim Public Company with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is E for L Aim Public Company (EFORL) overvalued or undervalued?
What is the fair value of EFORL?
What is the quality score of EFORL?
What is the revenue of E for L Aim Public Company (EFORL)?
What is the net profit margin of EFORL?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track E for L Aim Public Company and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.